Recent
studie
s have provided evidence that peptide
s a
s short a
s tripeptide
s do adopt preferredconformation
s. Here we report that the tripeptide Ala-Phe-Ala (AFA) in aqueou
s solution preferentiallyform
s an inver
se
G SRC="/images/gifchars/gamma.gif" BORDER=0 >-turn. Circular dichroism (CD) indicated the presence of a predominant turn structure,and Fourier transform infrared (FTIR) bands suggested the presence of a
ges/gifchars/gamma.gif" BORDER=0 >-turn forming a bifurcatedH-bond with the solvent molecules. The high-resolution structure was obtained by a combined use ofNMR spectroscopy and calculations. On the basis of 30 unambiguous ROESY-derived distance restraints(including the H
ges/gifchars/alpha.gif" BORDER=0>-NH NOE between Ala1 and Ala3 and a hydrogen bond between the CO group of Ala1and the NH group of Ala3), calculations clearly demonstrated the presence of an inverse
ges/gifchars/gamma.gif" BORDER=0 >-turn centeredon Phe2. From NOE data, we estimated a mole fraction for the
ges/gifchars/gamma.gif" BORDER=0 >-turn of 0.65. Since for AFA an extended
ges/gifchars/beta2.gif" BORDER=0 ALIGN="middle">-strand was also reported [Eker, F., Griebenow, K., Cao, X., Nafie, L. A., and Schweitzer-Stenner, R.(2004) Proc. Natl. Acad. Sci. U.S.A. 101, 10054-10059], we investigated the possibility that
ges/gifchars/gamma.gif" BORDER=0 >-turn and
ges/gifchars/beta2.gif" BORDER=0 ALIGN="middle">-strand may represent two major conformations. By using a best-fit procedure that calculated experimentalNOEs as weighted averages of the effects originating from both structures, we were able to calculate withgood accuracy the backbone NOEs at 280 K in terms of the two limiting conformers, yielding a molefraction for the
ges/gifchars/gamma.gif" BORDER=0 >-turn and
ges/gifchars/beta2.gif" BORDER=0 ALIGN="middle">-strand conformations of 0.60 and 0.40, respectively, in good agreement withthose found by NOE data. The implication of the existence of a preferred conformation by a small structuralelement is discussed in the context of the nucleation of protein folding events and the design of smallpeptide and peptidomimetic drugs.